Cefuroxime 500 mg + Clavulanic Acid 125 mg Formulation

Cefuroxime 500 mg + Clavulanic Acid 125 mg Tablets are a fixed-dose pharmaceutical combination formulated as a solid oral dosage form. The formulation contains two active pharmaceutical ingredients—Cefuroxime 500 mg and Clavulanic Acid 125 mg—incorporated into a single tablet with carefully selected pharmaceutical excipients.

The development of a combination tablet requires consideration of the individual physicochemical characteristics of both active ingredients, their compatibility with one another, and their interaction with the selected excipient system. Parameters such as particle size, flow properties, moisture sensitivity, blend uniformity, compression behavior, and stability are important during formulation development.

The specified strengths of Cefuroxime 500 mg + Clavulanic Acid 125 mg require accurate dispensing and controlled manufacturing to maintain consistency across individual tablets and production batches. For pharmaceutical companies developing a diversified product portfolio, this combination can be included within a structured oral-solid dosage range and a broader PCD Pharma Franchise portfolio.

Dual-Active Composition & Excipient Selection

The formulation is based on Cefuroxime 500 mg and Clavulanic Acid 125 mg. Both ingredients require controlled handling and suitable formulation conditions to maintain their specified quality characteristics.

Cefuroxime forms the higher-strength component of the formulation, while clavulanic acid is incorporated at a lower specified quantity. The difference in concentration requires appropriate blending and sampling strategies to achieve uniform distribution of both components.

Pharmaceutical excipients are selected according to the required formulation characteristics. Depending on the approved formulation, these may include diluents, binders, disintegrants, lubricants, glidants, stabilizing agents, and other functional ingredients.

Pre-formulation studies may evaluate compatibility between cefuroxime, clavulanic acid, and the selected excipients. Parameters such as particle characteristics, moisture behavior, flowability, compressibility, and chemical stability can be assessed before finalizing the formulation.

Particular attention can be given to the stability requirements of clavulanic acid. Appropriate formulation and packaging strategies may be established based on stability data to help preserve the specified quality of the finished product.

Manufacturing Process & Tablet Formation

The production of Cefuroxime 500 mg + Clavulanic Acid 125 mg Tablets begins with controlled receipt, sampling, identification, and testing of raw materials. Only materials meeting established specifications are released for manufacturing.

Accurate dispensing of both active ingredients and excipients is performed according to the approved batch manufacturing formula. Because the two active ingredients are present at different concentrations, controlled premixing and blending procedures may be used to achieve homogeneous distribution.

Depending on the formulation technology, manufacturing may involve sifting, pre-blending, granulation, drying, milling, final blending, lubrication, and compression. The selected process is established based on the characteristics of the active ingredients and excipients.

Manufacturing parameters such as mixing time, equipment load, ingredient addition sequence, and lubrication conditions can be controlled during production. In-process testing can help verify the uniformity of the blend before compression.

During tablet compression, parameters such as tablet weight, thickness, hardness, friability, compression force, and machine speed may be monitored. If film coating is incorporated into the formulation, coating conditions are also controlled to obtain consistent coverage and appearance.

Quality Control & Analytical Verification

Quality control is an essential part of manufacturing Cefuroxime 500 mg + Clavulanic Acid 125 mg Tablets. Because the product contains two active ingredients, analytical evaluation must appropriately assess each component within the finished formulation.

Testing may include identification and assay of cefuroxime and clavulanic acid, uniformity of dosage units, dissolution, disintegration, average weight, weight variation, hardness, friability, thickness, and visual appearance.

Analytical methods should be appropriately developed and validated for the combination formulation. Suitable methods allow the individual active ingredients to be identified and quantified accurately.

In-process controls may include blend uniformity, tablet weight, compression parameters, hardness, thickness, and appearance. Monitoring these attributes during manufacturing helps identify potential variations before completion of the batch.

Finished tablets can also undergo visual inspection for defects such as cracks, chipping, capping, lamination, discoloration, or coating irregularities where applicable.

A robust documentation system supports traceability from raw-material receipt through final batch release. Batch manufacturing records, raw-material test reports, dispensing documents, laboratory reports, in-process control records, packaging records, and final-release documents form important components of pharmaceutical quality assurance.

Stability & Protective Packaging Strategy

Stability assessment is particularly important for Cefuroxime 500 mg + Clavulanic Acid 125 mg Tablets because the formulation contains multiple active ingredients with their own stability characteristics. Stability studies can evaluate the product under defined temperature and humidity conditions throughout the designated study period.

Relevant parameters may include assay, dissolution, disintegration, appearance, degradation-related characteristics, and physical integrity. The stability data generated during development can support the selection of suitable packaging and storage specifications.

Depending on the approved formulation and stability requirements, the tablets may be packed in pharmaceutical-grade blister packs, alu-alu packs, strips, bottles, or other suitable container-closure systems.

Packaging should provide appropriate protection from environmental exposure and physical damage during transportation and storage. Particular consideration may be given to moisture protection where required by the formulation's stability profile.

Packaging-line controls can include seal integrity, batch coding, printing accuracy, tablet count, pack appearance, and overall container-closure quality. Proper labeling should include the product name, composition, strength, batch number, manufacturing details, expiry information, pack size, storage requirements, and other applicable regulatory particulars.

Product Portfolio Integration & Manufacturing Quality

Cefuroxime 500 mg + Clavulanic Acid 125 mg Tablets can form part of a diversified pharmaceutical portfolio containing combination formulations and other oral solid dosage products. Its dual-active composition requires coordinated attention to raw-material qualification, compatibility, blending uniformity, manufacturing controls, analytical testing, stability, and packaging.

For companies operating within the PCD Pharma Franchise segment, a systematically developed product range can support professional pharmaceutical distribution and product presentation. Consistent specifications, reliable manufacturing processes, appropriate packaging, and comprehensive documentation are important elements of portfolio management.

The manufacturing lifecycle begins with qualified raw materials and continues through accurate dispensing, controlled premixing, homogeneous blending, optimized tablet compression, quality testing, stability assessment, and final packaging. Each stage contributes to maintaining the defined composition and quality attributes.

With its specified combination of Cefuroxime 500 mg + Clavulanic Acid 125 mg, this tablet formulation can be developed through a quality-focused approach emphasizing ingredient uniformity, formulation stability, analytical accuracy, tablet integrity, protective packaging, and consistent batch-to-batch manufacturing. This systematic framework supports professional product development and integration into a broader pharmaceutical portfolio.